Improvement in quality of life for cancer patients treated with epoetin alfa.

Abstract

Anaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.

• Authors: S E Libretto, P J Barrett-Lee, K Branson, D W Gorst, R Kaczmarski, K McAdam, P Stevenson, R Thomas
• Journal: European journal of cancer care (Eur J Cancer Care (Engl)) Vol. 10 Issue 3 Pg. 183-91 (Sep 2001) ISSN: 0961-5423 [Print] England
• PMID: 11829381 (Publication Type: Case Reports, Journal Article)

Chemical References

• Hematinics
• Recombinant Proteins
• Erythropoietin
• Epoetin Alfa

Topics

• Aged
• Anemia (drug therapy, etiology)
• Epoetin Alfa
• Erythropoietin (therapeutic use)
• Fatal Outcome
• Female
• Hematinics (therapeutic use)
• Humans
• Male
• Middle Aged
• Neoplasms (blood, complications)
• Quality of Life
• Recombinant Proteins